• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Record of Telephone Conversation - Cervarix, July 26, 2009 PM

System Info - 100608  SHONE, DEANNA   27-Jul-2009 17:50:07  SHONEDE

RECORD OF TELEPHONE CONVERSATION

 

Submission Type: Original Application   Submission ID:  125259/0    Office: OVRR  

Product:

Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant

Applicant:                                                                       

GlaxoSmithKline Biologicals          

Telecon Date/Time:  26-JUL-2009 02:53 PM     Initiated by FDA?  Yes

Telephone Number:    

Communication Categorie(s):

Information Request

Author:  HELEN GEMIGNANI

Telecon Summary:

Information Request RE: HPV-009

FDA Participants:  

Non-FDA Participants:   

Trans-BLA Group: No

Related STNs:  None

Related PMCs:  None

Telecon Body:

 

From: Gemignani, Helen S
Sent: Sunday, July 26, 2009 2:53 PM
To: 'Matt.Whitman@gsk.com'
Cc: 'nicholas.perombelon@gsk.com'; 'Cynthia.A.D'Ambrosio@gsk.com'
Subject: Cervarix BLA - Information Request RE: HPV-009

In the safety report for subject PID 389954 (study HPV-009), the case report states the following:

"Follow-up received on 11 December 2007 : On 10 December 2007 a copy of the biopsy report from the National Cancer Institute of the United States was obtained : Diagnosis : colon, total colectomy : severe mucosal injury with penetrating ulcers, fibrinopurulent pseudomembranous exudate, inflammatory polyps and inflammatory pseudopolyps, bacterial and fungal elements are present on surface and luminal area. The differential diagnosis is broad and includes idiopathic inflammatory bowel disease (IBD), infections, ischemic or drug induced injury. This case was seen in consultation with the GI pathology section of the Armed Forces Institute of Pathology and they agree with out interpretation. They do not favor IBD as the most possible etiology. A copy of their report is in our files."

1) CBER requests submission of this report to the Cervarix BLA.

Helen Sullivan Gemignani
Regulatory Project Manager
FDA/CBER/OVRR
Division of Vaccines and Related Products Applications/Viral Vaccine Branch
(301) 827-3070